The migalastat GLP-HEK assay is the gold standard for determining amenability in patients with Fabry disease

Benzer Materyaller

• The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
  Yazar:: Benjamin, Elfrida R., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• In Vitro and In Vivo Amenability to Migalastat in Fabry Disease
  Yazar:: Lenders, Malte, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study
  Yazar:: Germain, Dominique P., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Baseline Characteristics of Fabry Disease “Amenable” Migalastat Patients in Argentinian Cohort
  Yazar:: Sebastián Jaurretche, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-01-01)
• Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
  Yazar:: Mauer, Michael, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)